- Home
- CANF vs PRPH Comparison
CANF vs PRPH Comparison
Compare CANF & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- PRPH
- Stock Information
- Founded
- CANF 1994
- PRPH 1989
- Country
- CANF Israel
- PRPH United States
- Employees
- CANF N/A
- PRPH N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- PRPH Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- PRPH Health Care
- Exchange
- CANF Nasdaq
- PRPH Nasdaq
- Market Cap
- CANF 14.8M
- PRPH 15.2M
- IPO Year
- CANF N/A
- PRPH 1997
- Fundamental
- Price
- CANF $1.10
- PRPH $0.36
- Analyst Decision
- CANF Strong Buy
- PRPH
- Analyst Count
- CANF 2
- PRPH 0
- Target Price
- CANF $14.00
- PRPH N/A
- AVG Volume (30 Days)
- CANF 68.3K
- PRPH 1.9M
- Earning Date
- CANF 06-17-2025
- PRPH 05-20-2025
- Dividend Yield
- CANF N/A
- PRPH N/A
- EPS Growth
- CANF N/A
- PRPH N/A
- EPS
- CANF N/A
- PRPH N/A
- Revenue
- CANF $674,000.00
- PRPH $5,845,000.00
- Revenue This Year
- CANF $461.72
- PRPH $221.82
- Revenue Next Year
- CANF N/A
- PRPH N/A
- P/E Ratio
- CANF N/A
- PRPH N/A
- Revenue Growth
- CANF N/A
- PRPH N/A
- 52 Week Low
- CANF $0.98
- PRPH $0.22
- 52 Week High
- CANF $4.69
- PRPH $4.94
- Technical
- Relative Strength Index (RSI)
- CANF 46.91
- PRPH 52.22
- Support Level
- CANF $1.07
- PRPH $0.23
- Resistance Level
- CANF $1.12
- PRPH $0.40
- Average True Range (ATR)
- CANF 0.03
- PRPH 0.05
- MACD
- CANF 0.02
- PRPH 0.00
- Stochastic Oscillator
- CANF 75.00
- PRPH 64.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.